Vertex Pharmaceuticals-Alpine Immune Sciences deal receives US antitrust clearance
Vertex Pharmaceuticals and Alpine Immune Sciences have received approval from the US antitrust authorities for their $4.9 billion deal, according to a Vertex filing with the US Securities and Exchange Commission.Vertex...To view the full article, register now.
Already a subscriber? Click here to view full article